

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GENEGO LAUNCHES METADRUG™ FOR SYSTEMS –ADME/Tox

St. Joseph, MI. January 14th, 2005 –GeneGo, Inc., A leading systems biology company, today announced the official launch of MetaDrug™ V1.0. MetaDrug™ is a pioneering Systems-ADME/Tox platform which combines software for predicting metabolites and over 40 ADME/Tox properties with visualization and analysis of toxicogenomics and metabolomics data. MetaDrug™ can be used as a stand alone product or together with MetaCore™, GeneGo's flagship analytical platform.

"MetaDrug™ is the first commercial product that merges ADME/Tox predictions in human with systems biology," said Dr. Sean Ekins, Vice President, Computational Biology. MetaDrug™ contains an extensive, expert curated database of small molecule content related to human drug metabolism, algorithms for predicting and prioritization of metabolites, the ability to highlight reactive metabolites and the most extensive set of predictive ADME/Tox models available. MetaDrug™ also enables analysis of toxicogenomics data that can be visualized on networks and on static pathways maps. The user can therefore interpret both chemical and biological data in the context of the whole organism, merging predictions with empirical data when available. MetaDrug™ will be useful for preclinical assessment of molecules and their predicted properties. MetaDrug™ is also complimentary with MetaCore™ enabling researchers to build and analyze protein-protein, protein-ligand and genetic interaction networks using GeneGo's comprehensive databases of human biology and active chemistry. Ultimately both products enable the prediction of interactions of a small molecule with both xenobiotic and endogenous metabolism, regulation and cellular signaling.

MetaDrug™ features maps, pathways and networks for human proteins related to ADME/Tox; a database of small molecules with kinetic data for human drug metabolizing enzymes, proprietary algorithms for rule-based metabolite prediction, highlighting of reactive metabolites, >40 QSAR models for ADME/Tox properties, descriptors relevant to ADME parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; two proprietary network building algorithms; flexible visualization and data exchange tools.

MetaCore™ features a comprehensive set of maps, pathways and networks for almost all known human proteins; parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; seven proprietary network building algorithms; flexible visualization and data exchange tools.

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. GeneGo's first product, MetaCore, is an original computational platform for integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, siRNA and other phenotypic data) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's second product, MetaDrug™, assists pharmaceutical scientists with the prediction of metabolites and their likely toxicity in humans. For more information, please visit the company's Web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are the trademarks of GeneGo, Inc.